{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:42:20Z","timestamp":1792982540458,"version":"4.5.0"},"reference-count":327,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018818","name":"Thematic Excellence Program","doi-asserted-by":"publisher","award":["TKP2021-EGA-29"],"award-info":[{"award-number":["TKP2021-EGA-29"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Richter Talentum Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Difficult-to-treat (D2T) rheumatoid arthritis (RA) remains a major clinical challenge, affecting a significant proportion of patients who experience persistent symptoms despite multiple therapeutic regimens. This narrative review provides a comprehensive overview of potential molecular and cellular mechanisms that may underlie the D2T RA phenotype. We synthesize evidence across a broad biological landscape\u2014the role of genetic and epigenetic factors, autoantibodies, and diverse immune cell subsets is detailed in the context of therapeutic resistance. Furthermore, we examine the potential role of synovial signatures and stromal cell-mediated pathways, which may drive chronicity independently of traditional immune targets. The review highlights the complex interplay of peripheral and central determinants that contribute to patient-reported outcomes such as pain. We also discuss comorbid conditions, environmental factors such as smoking and nutrition, and treatment-related factors relevant to the D2T population. By integrating these aspects, this work aims to facilitate better stratification and the identification of novel therapeutic targets for refractory disease.<\/jats:p>","DOI":"10.3390\/ijms27041860","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:14:32Z","timestamp":1771236872000},"page":"1860","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3525-7874","authenticated-orcid":false,"given":"Andr\u00e1s Mikl\u00f3s","family":"Dorg\u00f3","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Semmelweis University, 1023 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-5232","authenticated-orcid":false,"given":"Lilla","family":"Gunkl-T\u00f3th","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Semmelweis University, 1023 Budapest, Hungary"},{"name":"Department of Pharmacology and Pharmacotherapy, University of P\u00e9cs, 7624 P\u00e9cs, Hungary"},{"name":"(HUN-REN-PTE) Chronic Pain Research Group, Hungarian Research Network, University of P\u00e9cs, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Semmelweis University, 1023 Budapest, Hungary"},{"name":"Heart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary"},{"name":"Department of Genetics, Cell- and Immunobiology, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021","volume":"5","author":"Black","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","article-title":"The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review","volume":"41","author":"Almutairi","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Majnik, J., Cs\u00e1sz\u00e1r-Nagy, N., B\u00f6cskei, G., Bender, T., and Nagy, G. (2022). Non-pharmacological treatment in difficult-to-treat rheumatoid arthritis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.991677"},{"key":"ref_8","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: An area of unmet clinical need","volume":"57","author":"Jacobs","year":"2017","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e070856","DOI":"10.1136\/bmj-2022-070856","article-title":"Therapeutic advances in rheumatoid arthritis","volume":"384","author":"Brown","year":"2024","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.autrev.2018.06.001","article-title":"Mechanistic immunological based classification of rheumatoid arthritis","volume":"17","author":"McGonagle","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhao, J., Guo, S., Schrodi, S.J., and He, D. (2021). Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.790122"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102405","DOI":"10.1016\/j.jaut.2020.102405","article-title":"Precision medicine and management of rheumatoid arthritis","volume":"110","author":"Aletaha","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103914","DOI":"10.1016\/j.autrev.2025.103914","article-title":"In search of biomarkers for prediction of drug treatment responses in rheumatoid arthritis: Lessons learned and future perspectives","volume":"24","author":"Dara","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","article-title":"Personalized biological treatment for rheumatoid arthritis: A systematic review with a focus on clinical applicability","volume":"55","author":"Cuppen","year":"2015","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.40428","article-title":"Identification of Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial Histologic Features and RNA Sequencing Data","volume":"70","author":"Orange","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","article-title":"Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes","volume":"623","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/ard-2024-226228","article-title":"Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness","volume":"84","author":"Kubo","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-025-01291-0","article-title":"Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases","volume":"21","author":"Rao","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"152501","DOI":"10.1016\/j.semarthrit.2024.152501","article-title":"Machine learning in the prediction of treatment response in rheumatoid arthritis: A systematic review","volume":"68","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ard.2025.07.005","article-title":"Precision medicine and the chaos theory in rheumatoid arthritis","volume":"85","author":"Triaille","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Xie, W., Chen, T., Xiao, S., Huang, H., and Zhang, Z. (2025). Difficult-to-treat rheumatoid arthritis (part 1): Systematic review and meta-analysis on global prevalence. Ann. Rheum. Dis.","DOI":"10.1016\/j.ard.2025.10.007"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e001512","DOI":"10.1136\/rmdopen-2020-001512","article-title":"Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: A systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"RMD Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","article-title":"Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis","volume":"17","author":"Buch","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/rheumatology\/keac114","article-title":"Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: A narrative review with systematic literature search","volume":"61","author":"Roodenrijs","year":"2022","journal-title":"Rheumatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(24)00340-0","article-title":"The concept of difficult-to-treat disease in rheumatology: Where next?","volume":"7","author":"Nagy","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ero.2025.11.024","article-title":"Characterising subgroups of difficult-to-treat rheumatoid arthritis in real-world clinical settings","volume":"2","author":"Tan","year":"2026","journal-title":"EULAR Rheumatol. Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13075-024-03390-x","article-title":"Truth unveiled by time and the marbled definition of D2T-RA: Retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients","volume":"26","author":"Cincinelli","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/art.42767","article-title":"Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease with Distinct Inflammatory and Noninflammatory Phenotypes","volume":"76","author":"David","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"110655","DOI":"10.1016\/j.intimp.2023.110655","article-title":"Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis","volume":"122","author":"Guo","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/25785826.2023.2235734","article-title":"Pathophysiology and stratification of treatment-resistant rheumatoid arthritis","volume":"47","author":"Yamada","year":"2024","journal-title":"Immunol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41232-025-00367-4","article-title":"CX3CR1+ age-associated CD4+ T cells contribute to synovial inflammation in late-onset rheumatoid arthritis","volume":"45","author":"Akiyama","year":"2025","journal-title":"Inflamm. Regen."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ard.2025.06.073","article-title":"POS0713: Peripheral blood mononuclear cell transcriptomics and plasma metabolomics reveal the role of neuroinflammation and neuroplasticity in the background of difficult-to-treat rheumatoid arthritis","volume":"84","author":"Kun","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","first-page":"2684","article-title":"Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis","volume":"77","author":"Orsi","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.ard.2025.06.758","article-title":"POS1410: Dysregulated TLR pathways in difficult-to-treat rheumatoid arthritis: A propensity score-matched transcriptomic study","volume":"84","author":"Nishiura","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Yan, H., Zi, X., Yan, H., Zhang, X., Bai, J., Gao, C., Li, X., and Wang, C. (2025). The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1522893"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.immuni.2024.11.004","article-title":"Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis","volume":"57","author":"MacDonald","year":"2024","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ard.2025.07.023","article-title":"Clinical application of synovial biopsy in noninflammatory and persistent inflammatory refractory rheumatoid arthritis","volume":"85","author":"Giollo","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ruiz-Lim\u00f3n, P., Mena-V\u00e1zquez, N., Moreno-Indias, I., Lisbona-Monta\u00f1ez, J.M., Mucientes, A., Manrique-Arija, S., Redondo-Rodriguez, R., Cano-Garc\u00eda, L., Tinahones, F.J., and Fern\u00e1ndez-Nebro, A. (2025). Gut dysbiosis is associated with difficult-to-treat rheumatoid arthritis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1497756"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","article-title":"Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins","volume":"43","author":"MacGregor","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12016-012-8346-7","article-title":"Genetics of Rheumatoid Arthritis\u2014A Comprehensive Review","volume":"45","author":"Besenyei","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wysocki, T., Olesi\u0144ska, M., and Paradowska-Gorycka, A. (2020). Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice. Cells, 9.","DOI":"10.3390\/cells9051127"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.21739","article-title":"The HLA\u2013DRB1 shared epitope alleles are primarily a risk factor for anti\u2013cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis","volume":"54","author":"Verpoort","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.2015.3435","article-title":"Association of HLA-DRB1 Haplotypes with Rheumatoid Arthritis Severity, Mortality, and Treatment Response","volume":"313","author":"Viatte","year":"2015","journal-title":"JAMA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis","volume":"68","author":"Potter","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13075-016-1174-z","article-title":"A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy\u2014Results from a Swedish cohort study","volume":"18","author":"Jiang","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/tpj.2012.8","article-title":"Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis","volume":"13","author":"Wang","year":"2013","journal-title":"Pharmacogenom. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/annrheumdis-2012-202405","article-title":"Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis","volume":"72","author":"Mirkov","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Al-Sofi, R.F., Bergmann, M.S., Nielsen, C.H., Andersen, V., Skov, L., and Loft, N. (2024). The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115793"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"103581","DOI":"10.1016\/j.autrev.2024.103581","article-title":"Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts\u2019 consensus","volume":"23","author":"Ruscitti","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1038\/ncomms12460","article-title":"Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis","volume":"7","author":"Sieberts","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Yang, C., Li, D., Teng, D., Zhou, Y., Zhang, L., Zhong, Z., and Yang, G.-J. (2022). Epigenetic Regulation in the Pathogenesis of Rheumatoid Arthritis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.859400"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrrheum.2014.16","article-title":"Genetic and epigenetic predictors of responsiveness to treatment in RA","volume":"10","author":"Plant","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Nemtsova, M.V., Zaletaev, D.V., Bure, I.V., Mikhaylenko, D.S., Kuznetsova, E.B., Alekseeva, E.A., Beloukhova, M.I., Deviatkin, A.A., Lukashev, A.N., and Zamyatnin, A.A. (2019). Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.00570"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00109-015-1332-9","article-title":"Regulation and function of SIRT1 in rheumatoid arthritis synovial fibroblasts","volume":"94","author":"Engler","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Wang, S.S., Lewis, M.J., and Pitzalis, C. (2023). DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071987"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hageman, I., Mol, F., Atiqi, S., Joustra, V., Sengul, H., Henneman, P., Visman, I., Hakvoort, T., Nurmohamed, M., and Wolbink, G. (2023). Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1303231"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/art.39123","article-title":"DNA Methylome Signature in Synoviocytes From Patients with Early Rheumatoid Arthritis Compared to Synoviocytes From Patients with Longstanding Rheumatoid Arthritis","volume":"67","author":"Ai","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mucientes, A., Lisbona, J.M., Mena-V\u00e1zquez, N., Ruiz-Lim\u00f3n, P., Manrique-Arija, S., and Fern\u00e1ndez-Nebro, A. (2022). miRNA-Mediated Epigenetic Regulation of Treatment Response in RA Patients\u2014A Systematic Review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112989"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lehoczki, A., Ungvari, Z., Szappanos, \u00c1., Fekete, M., Gunkl-T\u00f3th, L., and Nagy, G. (2025). Geroscience insights into difficult-to-treat rheumatoid arthritis: The role of unhealthy aging, comorbidity, and therapeutic complexity. GeroScience.","DOI":"10.1007\/s11357-025-02049-y"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"eadt9846","DOI":"10.1126\/sciadv.adt9846","article-title":"Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes","volume":"11","author":"Hiitola","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"102392","DOI":"10.1016\/j.jaut.2019.102392","article-title":"An overview of autoantibodies in rheumatoid arthritis","volume":"110","author":"Huizinga","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/516736","article-title":"Gene-Gene and Gene-Environment Interactions Involving HLA-DRB1, PTPN22, and Smoking in Two Subsets of Rheumatoid Arthritis","volume":"80","author":"Padyukov","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/art.20553","article-title":"A gene\u2013environment interaction between smoking and shared epitope genes in HLA\u2013DR provides a high risk of seropositive rheumatoid arthritis","volume":"50","author":"Padyukov","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.21575","article-title":"A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA\u2013DR (shared epitope)\u2013restricted immune reactions to autoantigens modified by citrullination","volume":"54","author":"Klareskog","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e001228","DOI":"10.1136\/rmdopen-2020-001228","article-title":"Current view on the pathogenic role of anti-citrullinated protein antibodies in rheumatoid arthritis","volume":"7","author":"Catrina","year":"2021","journal-title":"RMD Open"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nri.2016.124","article-title":"The immunopathogenesis of seropositive rheumatoid arthritis: From triggering to targeting","volume":"17","author":"Catrina","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2018.05.004","article-title":"Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis","volume":"195","author":"Lingampalli","year":"2018","journal-title":"Clin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid Factor as a Potentiator of Anti\u2013Citrullinated Protein Antibody\u2013Mediated Inflammation in Rheumatoid Arthritis","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1136\/annrheumdis-2013-204543","article-title":"IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies","volume":"74","author":"Laurent","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.4049\/jimmunol.1402334","article-title":"IgM and IgA Rheumatoid Factors Purified from Rheumatoid Arthritis Sera Boost the Fc Receptor- and Complement-Dependent Effector Functions of the Disease-Specific Anti-Citrullinated Protein Autoantibodies","volume":"194","author":"Anquetil","year":"2015","journal-title":"J. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Lv, Q., Yin, Y., Li, X., Shan, G., Wu, X., Liang, D., Li, Y., and Zhang, X. (2014). The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNF\u03b1 Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0089442"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e001882","DOI":"10.1136\/rmdopen-2021-001882","article-title":"Predictors of response to TNF inhibitors in rheumatoid arthritis: An individual patient data pooled analysis of randomised controlled trials","volume":"7","author":"Sparfel","year":"2021","journal-title":"RMD Open"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: Results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2020","journal-title":"Rheumatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","article-title":"Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis","volume":"43","author":"Maneiro","year":"2013","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","article-title":"Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: Data from the \u2018Orencia and Rheumatoid Arthritis\u2019 registry","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: Pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: A meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2665-9913(20)30033-3","article-title":"Lessons for rituximab therapy in patients with rheumatoid arthritis","volume":"2","author":"Yusof","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e000742","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41598-023-50379-8","article-title":"Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: A real-world study","volume":"14","author":"Gich","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/keae544","article-title":"Difficult-to-treat rheumatoid arthritis: What have we learned and what do we still need to learn?","volume":"64","author":"Hofman","year":"2024","journal-title":"Rheumatology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/keae318","article-title":"Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient registry","volume":"64","author":"Paudel","year":"2024","journal-title":"Rheumatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/03009742.2023.2277542","article-title":"Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study","volume":"53","author":"Michitsuji","year":"2024","journal-title":"Scand. J. Rheumatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/S2665-9913(25)00252-8","article-title":"The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritis","volume":"8","author":"Triaille","year":"2026","journal-title":"Lancet Rheumatol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ketabchi, S., Russo, E., Benucci, M., Infantino, M., Manfredi, M., Cassar\u00e0, E.A.M., Li Gobbi, F., Mannoni, A., and Terenzi, R. (2025). Biopsy-Driven Synovial Pathophenotyping in RA: A New Approach to Personalized Treatment. J. Pers. Med., 15.","DOI":"10.3390\/jpm15120622"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11926-023-01129-2","article-title":"Synovial Tissue Insights into Heterogeneity of Rheumatoid Arthritis","volume":"26","author":"Jonsson","year":"2024","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/art.42295","article-title":"Synovial Inflammatory Pathways Characterize Anti-TNF\u2013Responsive Rheumatoid Arthritis Patients","volume":"74","author":"Wang","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","article-title":"Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): Two parallel, open-label, biopsy-driven, randomised trials","volume":"5","author":"Rivellese","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: Synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/annrheumdis-2021-222021","article-title":"Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S2665-9913(21)00061-8","article-title":"Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): An open-label, dose-finding, phase 1b trial","volume":"3","author":"Pratt","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/rheumatology\/keae357","article-title":"A double-blind, placebo-controlled, randomized multiple dose phase 1b trial of a CDK4\/6 inhibitor, TCK-276, in patients with active rheumatoid arthritis","volume":"64","author":"Tasaki","year":"2024","journal-title":"Rheumatology"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Nerviani, A., Di Cicco, M., Mahto, A., Lliso-Ribera, G., Rivellese, F., Thorborn, G., Hands, R., Bellan, M., Mauro, D., and Boutet, M.-A. (2020). A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNF\u03b1-Blockade in Rheumatoid Arthritis Patients. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00845"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1038\/s41467-025-60987-9","article-title":"Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis","volume":"16","author":"Lewis","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13075-024-03343-4","article-title":"Targeting pathogenic fibroblast-like synoviocyte subsets in rheumatoid arthritis","volume":"26","author":"Qian","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Huang, Y., Wu, Y., Liu, H., Chen, Y., Xie, Q., and Yin, G. (2025). Targeting fibroblast activation protein in rheumatoid arthritis: From molecular imaging to precision therapeutics. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1616618"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Li, L., Dai, F., Wang, L., Sun, Y., Mei, L., Ran, Y., and Ye, F. (2023). CCL13 and human diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1176639"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard-2024-225778","article-title":"ITGA5+ synovial fibroblasts orchestrate proinflammatory niche formation by remodelling the local immune microenvironment in rheumatoid arthritis","volume":"84","author":"Zheng","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Bhamidipati, K., McIntyre, A.B.R., Kazerounian, S., Ce, G., Wong, S.W., Tran, M., Prell, S.A., Lau, R., Khedgikar, V., and Altmann, C. (2026). Spatial patterning of fibroblast TGF\u03b2 signaling underlies treatment resistance in rheumatoid arthritis. Nat. Immunol.","DOI":"10.1101\/2025.03.14.642821"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.27359","article-title":"Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment","volume":"62","author":"Vital","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar4543","article-title":"High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study","volume":"16","author":"Daien","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/art.30599","article-title":"Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/art.38023","article-title":"CCL19, a B Cell Chemokine, Is Related to the Decrease of Blood Memory B Cells and Predicts the Clinical Response to Rituximab in Patients with Rheumatoid Arthritis","volume":"65","author":"Sellam","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/ar2686","article-title":"Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis","volume":"11","author":"Aeberli","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_115","first-page":"887","article-title":"Combination of B cell biomarkers as independent predictors of response in patients with rheumatoid arthritis treated with rituximab","volume":"33","author":"Tony","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/rheumatology\/kex012","article-title":"Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis","volume":"57","author":"Nakayamada","year":"2017","journal-title":"Rheumatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-015-0580-y","article-title":"CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis","volume":"17","author":"Mahmood","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12016-017-8603-x","article-title":"Memory B Cells and Response to Abatacept in Rheumatoid Arthritis","volume":"53","author":"Gazeau","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Adlowitz, D.G., Barnard, J., Biear, J.N., Cistrone, C., Owen, T., Wang, W., Palanichamy, A., Ezealah, E., Campbell, D., and Wei, C. (2015). Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128269"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Wang, T., Giltiay, N.V., Lood, C., Wang, N., and Han, B.K. (2025). Evaluation of B cell related markers and autoantibodies in rheumatoid arthritis patients treated with abatacept. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1504454"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/art.41941","article-title":"Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti\u2013Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti\u2013Tumor Necrosis Factor on B Cells","volume":"74","author":"Meednu","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/ard-2022-222605","article-title":"Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-\u03b1-mediated ERK1\/2 and JAK-STAT1 pathways","volume":"81","author":"Qin","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"104533","DOI":"10.1016\/j.cellimm.2022.104533","article-title":"Age-associated B cells indicate disease activity in rheumatoid arthritis","volume":"377","author":"Bao","year":"2022","journal-title":"Cell. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","article-title":"Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: Results from the pathobiology of early arthritis cohort (PEAC)","volume":"78","author":"Humby","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-Targeted T-Cell\u2013Engager Therapy for Autoimmune Disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12016-025-09113-7","article-title":"CAR T Cell Therapy for Rheumatoid Arthritis","volume":"68","author":"Freeley","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.37787","article-title":"Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis","volume":"65","author":"Bonelli","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1136\/annrheumdis-2018-214885","article-title":"Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell","volume":"78","author":"Takeshita","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Jiang, Q., Yang, G., Liu, Q., Wang, S., and Cui, D. (2021). Function and Role of Regulatory T Cells in Rheumatoid Arthritis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.626193"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41392-025-02326-4","article-title":"Regulatory T cells in homeostasis and disease: Molecular mechanisms and therapeutic potential","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13075-015-0526-4","article-title":"Peripheral blood CD4+CD25+CD127low regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: Increase in regulatory T cells correlates with clinical response","volume":"17","author":"Kikuchi","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/rheumatology\/keae196","article-title":"Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis","volume":"63","author":"Yoshida","year":"2024","journal-title":"Rheumatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.39091","article-title":"Helios Enhances Treg Cell Function in Cooperation with FoxP3","volume":"67","author":"Takatori","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-017-1309-x","article-title":"Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis","volume":"19","author":"Nakachi","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"751793","DOI":"10.1155\/2015\/751793","article-title":"Altered Immunoregulation in Rheumatoid Arthritis: The Role of Regulatory T Cells and Proinflammatory Th17 Cells and Therapeutic Implications","volume":"2015","author":"Alunno","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","article-title":"Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway","volume":"71","author":"Alzabin","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/ar3431","article-title":"Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy","volume":"13","author":"Chen","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13075-016-1197-5","article-title":"Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis","volume":"18","author":"Hull","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"30639","DOI":"10.1073\/pnas.2007935117","article-title":"Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells","volume":"117","author":"Hu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/rheumatology\/keac385","article-title":"IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via I\u03baB\u03b6-dependent induction of ELF3","volume":"62","author":"Kouri","year":"2022","journal-title":"Rheumatology"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Noack, M., Beringer, A., and Miossec, P. (2019). Additive or Synergistic Interactions Between IL-17A or IL-17F and TNF or IL-1\u03b2 Depend on the Cell Type. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01726"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: A proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40744-023-00620-7","article-title":"Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis","volume":"11","author":"Su","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/ard-2023-224225","article-title":"T follicular helper cells and T peripheral helper cells in rheumatic and musculoskeletal diseases","volume":"82","author":"Akiyama","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41577-022-00693-5","article-title":"The link between circulating follicular helper T cells and autoimmunity","volume":"22","author":"Walker","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/rheumatology\/keab454","article-title":"Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis","volume":"61","author":"Aldridge","year":"2021","journal-title":"Rheumatology"},{"key":"ref_149","first-page":"517","article-title":"Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis","volume":"64","author":"Uyaguari","year":"2024","journal-title":"Rheumatology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"eadt3955.","DOI":"10.1126\/sciimmunol.adt3955","article-title":"Stem-like and effector peripheral helper T cells comprise distinct subsets in rheumatoid arthritis","volume":"10","author":"Masuo","year":"2025","journal-title":"Sci. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrrheum.2016.91","article-title":"Macrophage heterogeneity in the context of rheumatoid arthritis","volume":"12","author":"Udalova","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2004.029751","article-title":"Synovial tissue macrophages: A sensitive biomarker for response to treatment in patients with rheumatoid arthritis","volume":"64","author":"Haringman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2007.080440","article-title":"The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor \u03b1 expression in the synovium","volume":"67","author":"Wijbrandts","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_156","first-page":"46","article-title":"Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3899\/jrheum.090348","article-title":"Synovial Tissue Sublining CD68 Expression Is a Biomarker of Therapeutic Response in Rheumatoid Arthritis Clinical Trials: Consistency Across Centers","volume":"36","author":"Bresnihan","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat. Med."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Kemble, S., and Croft, A.P. (2021). Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.715894"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/s41467-024-46564-6","article-title":"Axl and MerTK regulate synovial inflammation and are modulated by IL-6 inhibition in rheumatoid arthritis","volume":"15","author":"Nerviani","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41467-025-57361-0","article-title":"Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF\/JAK inhibitor treatment","volume":"16","author":"Xia","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"eaag3009","DOI":"10.1126\/science.aag3009","article-title":"Mapping the human DC lineage through the integration of high-dimensional techniques","volume":"356","author":"See","year":"2017","journal-title":"Science"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/ard-2022-223645","article-title":"Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance","volume":"82","author":"Yamada","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.molmed.2018.12.008","article-title":"Neutrophils in Rheumatoid Arthritis: Breaking Immune Tolerance and Fueling Disease","volume":"25","author":"Kaplan","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e13037","DOI":"10.1111\/eci.13037","article-title":"Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis","volume":"49","author":"Erre","year":"2019","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/14397595.2016.1214340","article-title":"Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy","volume":"27","author":"Ghang","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Fujisawa, Y., Watanabe, R., Okano, T., Onishi, A., Murakami, K., Ebina, K., Yamada, H., Yamashita, M., Takeuchi, T., and Yoshikawa, A. (2025). Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: The ANSWER cohort study. Rheumatology, keaf602.","DOI":"10.1093\/rheumatology\/keaf602"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s40744-024-00695-w","article-title":"Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis","volume":"11","author":"Taylor","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00296-019-04276-x","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-\u03b1 agents in patients with rheumatoid arthritis: A retrospective chart review analysis","volume":"39","author":"Lee","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13075-019-1999-3","article-title":"Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor","volume":"21","author":"Farutin","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1189\/jlb.5A0616-258R","article-title":"Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis","volume":"101","author":"Wright","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/art.43042","article-title":"Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1\/2 Inhibitor Baricitinib","volume":"77","author":"Kuley","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Wright, H.L., Lyon, M., Chapman, E.A., Moots, R.J., and Edwards, S.W. (2021). Rheumatoid Arthritis Synovial Fluid Neutrophils Drive Inflammation Through Production of Chemokines, Reactive Oxygen Species, and Neutrophil Extracellular Traps. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.584116"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.2147\/JIR.S503144","article-title":"Neutrophils in Rheumatoid Arthritis Synovium: Implications on Disease Activity and Inflammation State","volume":"18","author":"Deng","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41584-024-01155-z","article-title":"An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis","volume":"20","author":"Kirkham","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"eabj8186","DOI":"10.1126\/scitranslmed.abj8186","article-title":"Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors","volume":"14","author":"Shiers","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e100235","DOI":"10.1136\/bmjos-2021-100235","article-title":"Fibroblasts: The neglected cell type in peripheral sensitisation and chronic pain? A review based on a systematic search of the literature","volume":"6","author":"Shinotsuka","year":"2022","journal-title":"BMJ Open Sci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbi.2023.06.011","article-title":"Fibroblast-derived PI16 sustains inflammatory pain via regulation of CD206+ myeloid cells","volume":"112","author":"Garrity","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.1913444117","article-title":"The fibroblast-derived protein PI16 controls neuropathic pain","volume":"117","author":"Singhmar","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"eadk3506","DOI":"10.1126\/scitranslmed.adk3506","article-title":"Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis","volume":"16","author":"Bai","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"103015","DOI":"10.1016\/j.autrev.2021.103015","article-title":"The autoimmune aetiology of unexplained chronic pain","volume":"21","author":"Goebel","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/annrheumdis-2015-208094","article-title":"Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism","volume":"75","author":"Wigerblad","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1172\/JCI128010","article-title":"Neuronal Fc\u03b3RI mediates acute and chronic joint pain","volume":"129","author":"Wang","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1084\/jem.20181657","article-title":"Cartilage-binding antibodies induce pain through immune complex\u2013mediated activation of neurons","volume":"216","author":"Wigerblad","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.42429","article-title":"The Biology of Pain: Through the Rheumatology Lens","volume":"75","author":"Sunzini","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/ALN.0000000000002130","article-title":"Neuroinflammation and Central Sensitization in Chronic and Widespread Pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10067-011-1795-1","article-title":"Assessment of biocorrelates for brain involvement in female patients with rheumatoid arthritis","volume":"31","author":"Hamed","year":"2012","journal-title":"Clin. Rheumatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.40451","article-title":"Neurobiologic Features of Fibromyalgia Are Also Present Among Rheumatoid Arthritis Patients","volume":"70","author":"Basu","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Flodin, P., Martinsen, S., Altawil, R., Waldheim, E., Lampa, J., Kosek, E., and Fransson, P. (2016). Intrinsic Brain Connectivity in Chronic Pain: A Resting-State fMRI Study in Patients with Rheumatoid Arthritis. Front. Hum. Neurosci., 10.","DOI":"10.3389\/fnhum.2016.00107"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bbi.2019.06.024","article-title":"Altered cerebral pain processing of noxious stimuli from inflamed joints in rheumatoid arthritis: An event-related fMRI study","volume":"81","author":"Ellerbrock","year":"2019","journal-title":"Brain Behav. Immun."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41467-018-04648-0","article-title":"A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis","volume":"9","author":"Schrepf","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1073\/pnas.1011774108","article-title":"Blockade of TNF-\u03b1 rapidly inhibits pain responses in the central nervous system","volume":"108","author":"Hess","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/acr.25694","article-title":"Beyond Inflammation: Why Understanding the Brain Matters in Inflammatory Arthritis","volume":"78","author":"Kelleher","year":"2025","journal-title":"Arthritis Care Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/art.41440","article-title":"Association of Dysregulated Central Pain Processing and Response to Disease\u2013Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis","volume":"72","author":"Heisler","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/rheumatology\/keq282","article-title":"Fatigue in rheumatoid arthritis: Time for a conceptual model","volume":"50","author":"Hewlett","year":"2010","journal-title":"Rheumatology"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1093\/rheumatology\/keaa860","article-title":"Difficult-to-treat rheumatoid arthritis: Contributing factors and burden of disease","volume":"60","author":"Roodenrijs","year":"2020","journal-title":"Rheumatology"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Leon, L., Freites-N\u00fa\u00f1ez, D., Madrid, A., Rodriguez-Mariblanca, M., Fernandez-Gutierrez, B., and Abasolo, L. (2024). The potential role of fatigue in difficult-to-treat rheumatoid arthritis. BMC Rheumatol., 8.","DOI":"10.1186\/s41927-024-00423-5"},{"key":"ref_198","first-page":"e64011","article-title":"The Prevalence of Fibromyalgia in Rheumatoid Arthritis Patients Using the Fibromyalgia Assessment Screening Tool (FAST 4) Based on the Multidimensional Health Assessment Questionnaire (MDHAQ)","volume":"16","author":"Amine","year":"2024","journal-title":"Cureus"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Jurado-Priego, L.N., Cueto-Ure\u00f1a, C., Ram\u00edrez-Exp\u00f3sito, M.J., and Mart\u00ednez-Martos, J.M. (2024). Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies. Biomedicines, 12.","DOI":"10.3390\/biomedicines12071543"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-024-03432-4","article-title":"Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender","volume":"27","author":"Luciano","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/rheumatology\/kev306","article-title":"Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: Secondary analysis of a randomized controlled trial","volume":"55","author":"Matcham","year":"2015","journal-title":"Rheumatology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"152014","DOI":"10.1016\/j.semarthrit.2022.152014","article-title":"Psychological stress in rheumatoid arthritis: A systematic scoping review","volume":"55","author":"Doumen","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00296-024-05583-8","article-title":"Pain catastrophizing in rheumatic diseases: Prevalence, origin, and implications","volume":"44","author":"Wilk","year":"2024","journal-title":"Rheumatol. Int."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1084\/jem.20120571","article-title":"Neural reflexes in inflammation and immunity","volume":"209","author":"Andersson","year":"2012","journal-title":"J. Exp. Med."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"e70137","DOI":"10.1002\/acr2.70137","article-title":"Vagus Nerve Stimulation in Autoimmune Conditions: A Systematic Review","volume":"7","author":"Lombo","year":"2025","journal-title":"ACR Open Rheumatol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41591-025-04114-7","article-title":"Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: A pivotal randomized controlled trial","volume":"32","author":"Tesser","year":"2025","journal-title":"Nat. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semarthrit.2014.06.003","article-title":"Autonomic function and rheumatoid arthritis\u2014A systematic review","volume":"44","author":"Adlan","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ebiom.2016.02.029","article-title":"Autonomic Dysfunction Precedes Development of Rheumatoid Arthritis: A Prospective Cohort Study","volume":"6","author":"Koopman","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bbi.2017.04.003","article-title":"Modulation of experimental arthritis by vagal sensory and central brain stimulation","volume":"64","author":"Bassi","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/art.42637","article-title":"A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis","volume":"75","author":"Baker","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","article-title":"Genetic and environmental risk factors for rheumatoid arthritis","volume":"31","author":"Deane","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/ar2751","article-title":"Rheumatoid arthritis and smoking: Putting the pieces together","volume":"11","author":"Baka","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/rheumatology\/kew285","article-title":"Increased inflammation and disease activity among current cigarette smokers with rheumatoid arthritis: A cross-sectional analysis of US veterans","volume":"55","author":"Sokolove","year":"2016","journal-title":"Rheumatology"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/annrheumdis-2013-204486","article-title":"Smoking induces transcription of the heat shock protein system in the joints","volume":"73","author":"Ospelt","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/mr\/road013","article-title":"The effect of smoking on response to methotrexate in rheumatoid arthritis patients: A systematic review and meta-analysis","volume":"34","author":"Nayebirad","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"22279","DOI":"10.3390\/ijms151222279","article-title":"Smoking and Rheumatoid Arthritis","volume":"15","author":"Chang","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-\u03b1 therapy among patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology"},{"key":"ref_218","first-page":"1","article-title":"The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug","volume":"41","author":"Petersson","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"ref_219","first-page":"1010","article-title":"Cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian, Czech, and Slovak patients with rheumatoid arthritis: 104-week data from the CIMDORA prospective, non-interventional study","volume":"37","author":"Szekanecz","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03009742.2018.1466363","article-title":"Smoking and response to rituximab in rheumatoid arthritis: Results from an international European collaboration","volume":"48","author":"Chatzidionysiou","year":"2019","journal-title":"Scand. J. Rheumatol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/ken057","article-title":"Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group","volume":"47","author":"Westhoff","year":"2008","journal-title":"Rheumatology"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/rheumatology\/kel094","article-title":"Association between cigarette smoking and release of tumour necrosis factor \u03b1 and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis","volume":"45","author":"Glossop","year":"2006","journal-title":"Rheumatology"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40744-022-00464-7","article-title":"Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study","volume":"9","author":"Michelsen","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.semarthrit.2018.10.006","article-title":"Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis","volume":"48","author":"Quistrebert","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"H\u00e4ssler, S., Bachelet, D., Duhaze, J., Szely, N., Gleizes, A., Hacein-Bey Abina, S., Aktas, O., Auer, M., Avouac, J., and Birchler, M. (2020). Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Med., 17.","DOI":"10.1371\/journal.pmed.1003348"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"keac133.208","DOI":"10.1093\/rheumatology\/keac133.208","article-title":"P209 Subgroups of refractory rheumatoid arthritis and difficult to treat features highlight differences in comorbidity and smoking history\u2014A single-centre observational study","volume":"61","author":"Rogers","year":"2022","journal-title":"Rheumatology"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41584-018-0070-0","article-title":"Rheumatoid arthritis and the mucosal origins hypothesis: Protection turns to destruction","volume":"14","author":"Holers","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41584-021-00585-3","article-title":"The gut\u2013joint axis in rheumatoid arthritis","volume":"17","author":"Zaiss","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_229","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrrheum.2017.132","article-title":"The case for periodontitis in the pathogenesis of rheumatoid arthritis","volume":"13","author":"Potempa","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40496-014-0039-2","article-title":"Host Responses in the Link Between Periodontitis and Rheumatoid Arthritis","volume":"2","author":"Kobayashi","year":"2015","journal-title":"Curr. Oral Health Rep."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Kobayashi, T., Ito, S., Kobayashi, D., Shimada, A., Narita, I., Murasawa, A., Nakazono, K., and Yoshie, H. (2016). Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid Arthritis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154182"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-020-02269-x","article-title":"Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis?","volume":"22","author":"Tachibana","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Inchingolo, F., Inchingolo, A.M., Avantario, P., Settanni, V., Fatone, M.C., Piras, F., Di Venere, D., Inchingolo, A.D., Palermo, A., and Dipalma, G. (2023). The Effects of Periodontal Treatment on Rheumatoid Arthritis and of Anti-Rheumatic Drugs on Periodontitis: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417228"},{"key":"ref_235","first-page":"243","article-title":"Treatment of severe periodontitis may improve clinical disease activity in otherwise treatment-refractory rheumatoid arthritis patients","volume":"59","author":"Bender","year":"2019","journal-title":"Rheumatology"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.13359","article-title":"Gut microbiota as a sensor of autoimmune response and treatment for rheumatoid arthritis","volume":"325","author":"Lamba","year":"2024","journal-title":"Immunol. Rev."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm.3914","article-title":"The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1093\/rheumatology\/keae045","article-title":"Treatment response in rheumatoid arthritis is predicted by the microbiome: A large observational study in UK DMARD-naive patients","volume":"63","author":"Danckert","year":"2024","journal-title":"Rheumatology"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/keac454","article-title":"Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation that are reversed by inflammation control","volume":"62","author":"Audo","year":"2022","journal-title":"Rheumatology"},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Sanchez, P., Letarouilly, J.-G., Nguyen, Y., Sigaux, J., Barnetche, T., Czernichow, S., Flipo, R.-M., Sellam, J., and Da\u00efen, C. (2022). Efficacy of Probiotics in Rheumatoid Arthritis and Spondyloarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 14.","DOI":"10.3390\/nu14020354"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41423-023-00987-1","article-title":"Complex regulatory effects of gut microbial short-chain fatty acids on immune tolerance and autoimmunity","volume":"20","author":"Kim","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13075-023-03013-x","article-title":"Factors associated with the composition of the gut microbiome in patients with established rheumatoid arthritis and its value for predicting treatment responses","volume":"25","author":"Koh","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1016\/j.joca.2017.02.484","article-title":"Alterations of Gut Microbiome in Rheumatoid Arthritis","volume":"25","author":"Wu","year":"2017","journal-title":"Osteoarthr. Cartil."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/art.41622","article-title":"The Pretreatment Gut Microbiome Is Associated with Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis","volume":"73","author":"Artacho","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Gioia, C., Lucchino, B., Tarsitano, M.G., Iannuccelli, C., and Di Franco, M. (2020). Dietary Habits and Nutrition in Rheumatoid Arthritis: Can Diet Influence Disease Development and Clinical Manifestations?. Nutrients, 12.","DOI":"10.3390\/nu12051456"},{"key":"ref_246","first-page":"487","article-title":"Interaction between dietary sodium and smoking increases the risk for rheumatoid arthritis: Results from a nested case\u2013control study","volume":"54","author":"Johansson","year":"2014","journal-title":"Rheumatology"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature11868","article-title":"Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells","volume":"496","author":"Kleinewietfeld","year":"2013","journal-title":"Nature"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature11984","article-title":"Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1","volume":"496","author":"Wu","year":"2013","journal-title":"Nature"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"e056255","DOI":"10.1136\/bmjopen-2021-056255","article-title":"Association of rheumatoid arthritis and high sodium intake with major adverse cardiovascular events: A cross-sectional study from the seventh Korean National Health and Nutrition Examination Survey","volume":"11","author":"Bae","year":"2021","journal-title":"BMJ Open"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Li, D., Li, J., Li, Y., and Guan, Y. (2025). Dietary sodium intake and all-cause mortality in rheumatoid arthritis: An NHANES analysis (2003\u20132018). Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1518697"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/nutrit\/nuaa033","article-title":"Rheumatoid arthritis and dietary interventions: Systematic review of clinical trials","volume":"79","author":"Philippou","year":"2020","journal-title":"Nutr. Rev."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1017\/S0007114515002718","article-title":"Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis","volume":"114","author":"Proudman","year":"2015","journal-title":"Br. J. Nutr."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","article-title":"Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: Different sides of the same coin?","volume":"62","author":"Dey","year":"2022","journal-title":"Rheumatology"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"SI271","DOI":"10.1093\/rheumatology\/kead352","article-title":"Viewpoint: Could better understanding of risk factors for comorbidities pave the way towards personalized therapy in rheumatoid arthritis?","volume":"62","author":"Majnik","year":"2023","journal-title":"Rheumatology"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/kez037","article-title":"Polypharmacy is associated with treatment response and serious adverse events: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1093\/rheumatology\/keae325","article-title":"Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis","volume":"64","author":"Takanashi","year":"2024","journal-title":"Rheumatology"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"ref_259","first-page":"450","article-title":"Obesity in rheumatoid arthritis","volume":"50","author":"Metsios","year":"2010","journal-title":"Rheumatology"},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"Hoffman, E., Rahat, M.A., Feld, J., Elias, M., Rosner, I., Kaly, L., Lavie, I., Gazitt, T., and Zisman, D. (2019). Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184633"},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Novella-Navarro, M., Van Den Rym, A., L\u00f3pez-Pedrera, C., Mart\u00ednez-Feito, A., Nieto-Carvalhal, B., Reche, K., L\u00f3pez-Medina, C., Escudero-Contreras, A., Nozal, P., and Miranda-Car\u00fas, M.E. (2025). Do Obesity and Adipose Tissue Cytokines Influence the Response to Janus Kinase Inhibitors in Rheumatoid Arthritis?. Nutrients, 17.","DOI":"10.3390\/nu17050820"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","article-title":"Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis","volume":"86","author":"Shan","year":"2019","journal-title":"Jt. Bone Spine"},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Singh, S., Facciorusso, A., Singh, A.G., Casteele, N.V., Zarrinpar, A., Prokop, L.J., Grunvald, E.L., Curtis, J.R., and Sandborn, W.J. (2018). Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS ONE, 13, Correctin in PLoS ONE 2018, 13, e0203499. https:\/\/doi.org\/10.1371\/journal.pone.0203499.","DOI":"10.1371\/journal.pone.0195123"},{"key":"ref_264","first-page":"1726","article-title":"Obesity and response to biological therapy in rheumatoid arthritis: The role of body mass index and adipose tissue cytokines","volume":"40","author":"Genre","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1759720X241308027","DOI":"10.1177\/1759720X241308027","article-title":"Impact of obesity on clinical outcomes and treatment continuation in rheumatoid arthritis patients receiving non-TNF-targeted therapies","volume":"16","author":"Park","year":"2024","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jbspin.2014.12.006","article-title":"Obesity reduces the drug survival of second line biological drugs following a first TNF-\u03b1 inhibitor in rheumatoid arthritis patients","volume":"82","author":"Iannone","year":"2015","journal-title":"Jt. Bone Spine"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"e002103","DOI":"10.1136\/rmdopen-2021-002103","article-title":"Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: An analysis of pooled data from phase 3 studies","volume":"8","author":"Dikranian","year":"2022","journal-title":"RMD Open"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3899\/jrheum.150224","article-title":"Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis: A Systematic Review and Metaanalysis","volume":"42","author":"Vidal","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-016-1146-3","article-title":"Body mass index and extent of MRI-detected inflammation: Opposite effects in rheumatoid arthritis versus other arthritides and asymptomatic persons","volume":"18","author":"Mangnus","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/rmdopen-2020-001511","article-title":"Diagnostic issues in difficult-to-treat rheumatoid arthritis: A systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"RMD Open"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"10420","DOI":"10.1038\/s41598-019-46927-w","article-title":"Overweight\/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis","volume":"9","author":"Alivernini","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-020-00933-4","article-title":"The Impact of Obesity on Disease Activity and Treatment Response in Rheumatoid Arthritis","volume":"22","author":"Poudel","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_273","first-page":"115","article-title":"Diabetes mellitus risk factors in rheumatoid arthritis: A systematic review and meta-analysis","volume":"33","author":"Jiang","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital","volume":"62","author":"Hecquet","year":"2023","journal-title":"Rheumatology"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cei.12667","article-title":"Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1\u03b2 via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: A possible implication for therapeutic decision in these patients","volume":"182","author":"Ruscitti","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"Ruscitti, P., Masedu, F., Alvaro, S., Air\u00f2, P., Battafarano, N., Cantarini, L., Cantatore, F.P., Carlino, G., D\u2019Abrosca, V., and Frassi, M. (2019). Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1002901"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.39537","article-title":"Risk of Incident Diabetes Mellitus Associated with the Dosage and Duration of Oral Glucocorticoid Therapy in Patients with Rheumatoid Arthritis","volume":"68","author":"Movahedi","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-023-03165-w","article-title":"Unveiling difficult-to-treat rheumatoid arthritis: Long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry","volume":"25","author":"Jung","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","article-title":"Atherosclerosis in rheumatoid arthritis: Is it all about inflammation?","volume":"11","author":"Skeoch","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41584-018-0022-8","article-title":"Microvascular endothelial dysfunction in rheumatoid arthritis","volume":"14","author":"Bordy","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/annrheumdis-2013-204250","article-title":"Angiogenic T cells are decreased in rheumatoid arthritis patients","volume":"74","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2011-200493","article-title":"Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis","volume":"71","author":"Lee","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Yan, J., Yang, S., Han, L., Ba, X., Shen, P., Lin, W., Li, T., Zhang, R., Huang, Y., and Huang, Y. (2023). Dyslipidemia in rheumatoid arthritis: The possible mechanisms. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1254753"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-025-07824-y","article-title":"Association of Th17\/Treg immune imbalance and cardiovascular complications in RA patients: Retrospective cohort study in refractory subgroups","volume":"45","author":"Su","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","article-title":"Cardiovascular effects of approved drugs for rheumatoid arthritis","volume":"17","author":"Atzeni","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","article-title":"Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: From the FIRST Registry","volume":"24","author":"Ochi","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: Update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The Lung in Rheumatoid Arthritis","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_293","first-page":"280","article-title":"Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms","volume":"67","author":"Paulin","year":"2015","journal-title":"Rev. Investig. Clin."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/BOR.0000000000000238","article-title":"The lung in rheumatoid arthritis, cause or consequence?","volume":"28","author":"Chatzidionisyou","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"152561","DOI":"10.1016\/j.semarthrit.2024.152561","article-title":"Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"69","author":"Zhang","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_297","doi-asserted-by":"crossref","unstructured":"Steele, H., Cheng, J., Willicut, A., Dell, G., Breckenridge, J., Culberson, E., Ghastine, A., Tardif, V., and Herro, R. (2023). TNF superfamily control of tissue remodeling and fibrosis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1219907"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"105339","DOI":"10.1016\/j.ebiom.2024.105339","article-title":"Therapeutic single-cell landscape: Methotrexate exacerbates interstitial lung disease by compromising the stemness of alveolar epithelial cells under systemic inflammation","volume":"108","author":"Chang","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_299","doi-asserted-by":"crossref","unstructured":"Najm, A., Ferguson, L.D., and McInnes, I.B. (2025). Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis. Arthritis Rheumatol.","DOI":"10.1002\/art.43376"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S204730","article-title":"Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: Angel or demon?","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"e002777","DOI":"10.1136\/rmdopen-2022-002777","article-title":"Interstitial lung disease in rheumatoid arthritis: Incidence, prevalence and related drug prescriptions between 2007 and 2020","volume":"9","author":"Albrecht","year":"2023","journal-title":"RMD Open"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","article-title":"Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: A retrospective, active-comparator, new-user, cohort study","volume":"7","author":"England","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"e233640","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis Treated with Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice","volume":"60","author":"Takanashi","year":"2021","journal-title":"Rheumatology"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2012","journal-title":"Rheumatology"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/acr.23426","article-title":"Impact of Sustained Remission on the Risk of Serious Infection in Patients with Rheumatoid Arthritis","volume":"70","author":"Accortt","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"e000935","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: A US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/1744666X.2023.2247158","article-title":"Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: Challenge and outlook","volume":"19","author":"Sonomoto","year":"2023","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_312","first-page":"388","article-title":"2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer","volume":"84","author":"Sebbag","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrrheum.2013.92","article-title":"The influence of ageing on the development and management of rheumatoid arthritis","volume":"9","author":"Boots","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1093\/rheumatology\/keaf432","article-title":"Eye-openers for advanced management of elderly-onset rheumatoid arthritis","volume":"64","author":"Dag","year":"2025","journal-title":"Rheumatology"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/annrheumdis-2021-220315","article-title":"Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Takanashi","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2025.04.040","article-title":"Difficult-to-treat rheumatoid arthritis among elderly patients from the KOBIO registry","volume":"137","author":"Jung","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40266-022-00976-5","article-title":"Difficult-to-Treat Rheumatoid Arthritis in Older Adults: Implications of Ageing for Managing Patients","volume":"39","author":"Balsa","year":"2022","journal-title":"Drugs Aging"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2013","journal-title":"Rheumatology"},{"key":"ref_320","doi-asserted-by":"crossref","unstructured":"Pizano-Martinez, O., Mendieta-Condado, E., V\u00e1zquez-Del Mercado, M., Mart\u00ednez-Garc\u00eda, E.A., Chavarria-Avila, E., Ortu\u00f1o-Sahag\u00fan, D., and M\u00e1rquez-Aguirre, A.L. (2023). Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases. J. Clin. Med., 12.","DOI":"10.3390\/jcm12093271"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ero.2025.06.002","article-title":"Difficult-to-treat or clinical inertia?: The importance of earnest shared decision making in the management of rheumatoid arthritis","volume":"1","author":"Kaneko","year":"2025","journal-title":"EULAR Rheumatol. Open"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1093\/rheumatology\/keab130","article-title":"Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: A concept mapping study","volume":"60","author":"Roodenrijs","year":"2021","journal-title":"Rheumatology"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"103437","DOI":"10.1016\/j.autrev.2023.103437","article-title":"To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debate","volume":"23","author":"Cutolo","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/ard-2023-224670","article-title":"Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the \u2018JAK-pot\u2019 study)","volume":"83","author":"Aymon","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1093\/rheumatology\/keae265","article-title":"Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: The ANSWER cohort study","volume":"63","author":"Watanabe","year":"2024","journal-title":"Rheumatology"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"e006271","DOI":"10.1136\/rmdopen-2025-006271","article-title":"Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis","volume":"11","author":"Nagy","year":"2025","journal-title":"RMD Open"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1860\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:23:56Z","timestamp":1771237436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/4\/1860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":327,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27041860"],"URL":"https:\/\/doi.org\/10.3390\/ijms27041860","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}